Recombinant EphB4-HSA fusion protein
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Recombinant EphB4-HSA fusion protein, covering 2025-10-22 to 2026-06-08. Get the full timeline:
Most recent: Clinical Trial Results: Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent [Phase 2]